Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose PTCy, abatacept, and tacrolimus for GVHD prevention
NCT05621759Phase 2Active, not recruiting
- Sponsor
- NYU Langone Health
- Start
- Sep 2022
- Primary completion
- Jan 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of abatacept in graft-versus-host disease (GVHD), sponsored by NYU Langone Health. Started Sep 2022; status: active, not recruiting.
02
Drugs
abatacept
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05621759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05621759.